Table 2.
Meta-analysis of immune cells and prognostic indices in EC patients.
| Group | Study number | Number of case | Pooled result, HR (95% CI) | PZ value | PH value | I 2 |
|---|---|---|---|---|---|---|
| CD8-OS | 5 | 740 | 0.201 (0.076-0.533) | 0.001 | 0.104 | 45.2% |
| CD8-PFS-a/b | 3 | 397 | 0.308 (0.139-0.683)/0.306 (0.137-0.687) | 0.004 | 0.555/0.554 | 0.0% |
| CD8-DSS | 2 | 673 | 0.366 (0.222-0.604) | 0.000 | 0.353 | 0.0% |
| CD8-DFS | 2 | 673 | 0.466 (0.329-0.660) | 0.000 | 0.396 | 0.0% |
| FoxP3+ T cell-OS | 3 | 352 | 1.264 (0.419-3.812) | 0.678 | 0.212 | 35.6% |
| FoxP3+ T cell-RFS | 2 | 273 | 1.000 (0.995-1.005) | 0.999 | 0.655 | 0.0% |
| CD45RO+ T cell-OS | 2 | 478 | 0.415 (0.241-0.714) | 0.001 | 0.638 | 0.0% |
| TAM-OS | 3 | 425 | 1.985 (0.771-5.113) | 0.156 | 0.628 | 0.0% |
| TAM-RFS-c/d | 4 | 479 | 3.423 (1.289-9.094)/1.770 (0.458-6.843) | 0.014/0.408 | 0.364/0.068 | 5.9%/57.8% |
| TAM-RFS-e/f | 4 | 479 | 2.369 (1.003-5.598)/2.258 (0.966-5.282) | 0.049/0.06 | 0.403/0.373 | 0.0%/3.9% |
PZ: p value of the Z-test; PH: p value of the heterogeneity test.